229 related articles for article (PubMed ID: 34347394)
21. Clinical values of gene alterations as marker of minimal residual disease in non-M3 acute myeloid leukemia.
Yu T; Chi J; Wang L
Hematology; 2021 Dec; 26(1):848-859. PubMed ID: 34674615
[TBL] [Abstract][Full Text] [Related]
22. Next-generation sequencing-based multigene mutational screening for acute myeloid leukemia using MiSeq: applicability for diagnostics and disease monitoring.
Luthra R; Patel KP; Reddy NG; Haghshenas V; Routbort MJ; Harmon MA; Barkoh BA; Kanagal-Shamanna R; Ravandi F; Cortes JE; Kantarjian HM; Medeiros LJ; Singh RR
Haematologica; 2014 Mar; 99(3):465-73. PubMed ID: 24142997
[TBL] [Abstract][Full Text] [Related]
23. Revealing the Mysteries of Acute Myeloid Leukemia: From Quantitative PCR through Next-Generation Sequencing and Systemic Metabolomic Profiling.
Panuzzo C; Jovanovski A; Ali MS; Cilloni D; Pergolizzi B
J Clin Med; 2022 Jan; 11(3):. PubMed ID: 35159934
[TBL] [Abstract][Full Text] [Related]
24. Molecular Malfeasance Mediating Myeloid Malignancies: The Genetics of Acute Myeloid Leukemia.
King RL; Bagg A
Methods Mol Biol; 2017; 1633():1-17. PubMed ID: 28735477
[TBL] [Abstract][Full Text] [Related]
25. Influence of new molecular prognostic markers in patients with karyotypically normal acute myeloid leukemia: recent advances.
Mrózek K; Döhner H; Bloomfield CD
Curr Opin Hematol; 2007 Mar; 14(2):106-14. PubMed ID: 17255787
[TBL] [Abstract][Full Text] [Related]
26. Role of Minimal Residual Disease Testing in Acute Myeloid Leukemia.
Chen X; Cherian S
Clin Lab Med; 2021 Sep; 41(3):467-483. PubMed ID: 34304776
[TBL] [Abstract][Full Text] [Related]
27. Patient-tailored analysis of minimal residual disease in acute myeloid leukemia using next-generation sequencing.
Malmberg EB; Ståhlman S; Rehammar A; Samuelsson T; Alm SJ; Kristiansson E; Abrahamsson J; Garelius H; Pettersson L; Ehinger M; Palmqvist L; Fogelstrand L
Eur J Haematol; 2017 Jan; 98(1):26-37. PubMed ID: 27197529
[TBL] [Abstract][Full Text] [Related]
28. Molecular Testing in CML between Old and New Methods: Are We at a Turning Point?
Soverini S; Bernardi S; Galimberti S
J Clin Med; 2020 Nov; 9(12):. PubMed ID: 33261150
[TBL] [Abstract][Full Text] [Related]
29. Identification of two novel mutations in human acute myeloid leukemia cases.
O'Brien G; Zyla J; Manola KN; Pagoni MN; Polanska J; Badie C
Leuk Lymphoma; 2021 Feb; 62(2):454-461. PubMed ID: 33161783
[TBL] [Abstract][Full Text] [Related]
30. How I investigate acute myeloid leukemia.
Narayanan D; Weinberg OK
Int J Lab Hematol; 2020 Feb; 42(1):3-15. PubMed ID: 31820579
[TBL] [Abstract][Full Text] [Related]
31. The utility of next-generation sequencing in diagnosis and monitoring of acute myeloid leukemia and myelodysplastic syndromes.
Duncavage EJ; Tandon B
Int J Lab Hematol; 2015 May; 37 Suppl 1():115-21. PubMed ID: 25976969
[TBL] [Abstract][Full Text] [Related]
32. Minimal/Measurable Residual Disease Detection in Acute Leukemias by Multiparameter Flow Cytometry.
Fuda F; Chen W
Curr Hematol Malig Rep; 2018 Dec; 13(6):455-466. PubMed ID: 30446941
[TBL] [Abstract][Full Text] [Related]
33. Mutational spectrum and risk stratification of intermediate-risk acute myeloid leukemia patients based on next-generation sequencing.
Wang B; Liu Y; Hou G; Wang L; Lv N; Xu Y; Xu Y; Wang X; Xuan Z; Jing Y; Li H; Jin X; Deng A; Wang L; Gao X; Dou L; Liang J; Chen C; Li Y; Yu L
Oncotarget; 2016 May; 7(22):32065-78. PubMed ID: 27062340
[TBL] [Abstract][Full Text] [Related]
34. Biomarkers in Acute Myeloid Leukemia: Leveraging Next Generation Sequencing Data for Optimal Therapeutic Strategies.
El Achi H; Kanagal-Shamanna R
Front Oncol; 2021; 11():748250. PubMed ID: 34660311
[TBL] [Abstract][Full Text] [Related]
35. Comparison between karyotyping-FISH-reverse transcription PCR and RNA-sequencing-fusion gene identification programs in the detection of KAT6A-CREBBP in acute myeloid leukemia.
Panagopoulos I; Torkildsen S; Gorunova L; Tierens A; Tjønnfjord GE; Heim S
PLoS One; 2014; 9(5):e96570. PubMed ID: 24798186
[TBL] [Abstract][Full Text] [Related]
36. Genetic tests to evaluate prognosis and predict therapeutic response in acute myeloid leukemia.
Gulley ML; Shea TC; Fedoriw Y
J Mol Diagn; 2010 Jan; 12(1):3-16. PubMed ID: 19959801
[TBL] [Abstract][Full Text] [Related]
37.
Mroczkowska-Bękarciak A; Wróbel T
Front Genet; 2023; 14():1241912. PubMed ID: 37745842
[TBL] [Abstract][Full Text] [Related]
38. Genetic Characterization and Risk Stratification of Acute Myeloid Leukemia.
Pourrajab F; Zare-Khormizi MR; Hashemi AS; Hekmatimoghaddam S
Cancer Manag Res; 2020; 12():2231-2253. PubMed ID: 32273762
[TBL] [Abstract][Full Text] [Related]
39. [Using next generation sequencing technology to analyze gene mutations in patients with acute myeloid leukemia and the impact on prognosis].
Zhao CX; Wang JM; Li JM; Zou SH; Chen FY; Liang AB; Hou J; Hu XX; Zhang YX; Gu SY; Zhu JY; Li P; Du J; Yang YN; Qin YW; Wang XR; Wang C
Zhonghua Yi Xue Za Zhi; 2019 Oct; 99(40):3145-3151. PubMed ID: 31694105
[No Abstract] [Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
